WO2010062279A1 - Способ получения рекомбинантного инсулина человека - Google Patents
Способ получения рекомбинантного инсулина человека Download PDFInfo
- Publication number
- WO2010062279A1 WO2010062279A1 PCT/UA2009/000025 UA2009000025W WO2010062279A1 WO 2010062279 A1 WO2010062279 A1 WO 2010062279A1 UA 2009000025 W UA2009000025 W UA 2009000025W WO 2010062279 A1 WO2010062279 A1 WO 2010062279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant
- insulin
- polypeptide
- encodes
- plasmid dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the recombinant plasmid DNA site that encodes a hybrid polypeptide with the amino acid sequence of human proinsulin is part of plasmid pMUT12 and has the following structure:
- the com site a polypeptide with the amino acid sequence of human proinsulin, is part of the plasmid pDIM07 and has the following structure:
- the method is carried out as described below.
- expression vectors may contain a promoter region, a translation start signal, human proinsulin cDNA with or without modifications introduced into the C-peptide sequence, and an optimized prepeptide separated from proinsulin by the trypsin recognition site.
- Optimum for the present invention is recombinant plasmid DNA, which contains the integrated DNA as described above. Selected plasmids of the invention include pY-proins, pMUT12, pISYN2, and derivatives thereof.
- the invention also describes a process for producing a recombinant DNA molecule. This process involves cloning the corresponding vector of the DNA insert, which encodes the full-sized form of proinsulin, as well as analogues, homologs and precursors of the polypeptide, which are converted to insulin.
- the DNA sequence is cloned in the correct position and in the desired reading frame with the expression control sequence.
- the bacterial cells are destroyed by lysis - in order to release inclusion bodies that contain the insulin precursor polypeptide.
- bacterial cells are resuspended in a buffer solution at a pH of 6.0 to 9.0 and an ionic strength in the range of 0.0 IM to 2M. Any suitable salt, including NaCl, may be used. to maintain an appropriate level of ionic strength.
- cell lysis is carried out under conditions in which cell fragments are sufficiently destroyed and do not accumulate in the sediment during low-speed centrifugation.
- Cell lysis is carried out using commonly used methods, such as mechanical methods (in particular, cyclic freezing / thawing; use of a Microfludizer or Frepsh press; or an ultrasonic generator) or enzymatic methods (such as lysozyme treatment). In general, it is recommended that cells be lysed at a reduced temperature (i.e., less than 20 degrees C).
- Inclusion bodies are separated from cell fragments using any convenient method (for example, centrifugation), then washed if necessary. Inclusion bodies are usually washed by resuspending them in a buffer with the addition of detergent (for example, Triton X-100), then the inclusion bodies are again collected. The washed inclusion bodies are then dissolved in a solubilization buffer that contains a high concentration of a chaotropic agent (for example, urea or guanidine hydrochloride) and a reducing reagent at an optimal pH value.
- a chaotropic agent for example, urea or guanidine hydrochloride
- the urea concentration in the solubilization buffer is between 6M and 8M, mainly 7M, and the concentration of guanidine hydrochloride is from 5 to 7M, preferably 6M.
- the pH of the solubilization buffer varies from 7.5 to 11.0, mainly from 8.5 to 9.0. Any pH buffering agent (such as Tris, HEPES, MOPS, trisipe, etc.) can be used.
- the pH buffering agent is added to the solubilization buffer at a concentration that provides an effective buffer capacity, for example, from 10 to about 100 mM, preferably 20 mM.
- Reducing reagents are an integral part of the solubilization buffer - to restore disulfide bonds and to maintain cysteine residues in reduced form.
- reducing agents are used: beta-mercaptoethanol, dithiothreitol, etc.
- the optimal concentration of beta-mercaptoethanol is between 20 and 20OMM, mainly between 100 and 150mM.
- Dissolution of inclusion bodies is generally carried out over a period of six hours to about 24 hours, preferably within 8 hours. Dissolution can be carried out at room temperature or lowered temperature, usually from 4 degrees to 24 degrees C, mainly at 20 degrees C. After the dissolution of inclusion bodies is completed, the solution of the recovered polypeptide is clarified to remove the insoluble residue. Clarification can be accomplished using high speed centrifugation.
- the reconstituted proinsulin precursor is then diluted with refolding buffer. Dilution is carried out by adding a solution of inclusion bodies to the buffer for refolding or by simultaneously supplying a buffer and solution of inclusion bodies to the tank for refolding.
- the inclusion Taurus solution can be diluted from about 10 to 200-fold, preferably 100-fold by refolding buffer.
- the final concentration of the polypeptide after dissolution can be from about 0.01 mg / ml to 5 mr / ml, preferably 1 mg / ml.
- the refolding buffer typically contains a pH buffering agent, a redox couple, a cationic chelator, free radical breakdown preservatives for the polypeptide and some other low molecular weight additives.
- the refolding process is carried out at a temperature of approximately 4 to 24 degrees C, mainly at 10 degrees C.
- the incubation time is generally from about 2 to 20 hours, preferably about 6 hours.
- the main components of the refolding buffer include glycine in a concentration of from about 0.5 mM to 20 mM; EDTA from about 0.1 mM to 5 mM; glycerin - from about 1% to 20%.
- a correctly laid insulin precursor can be concentrated, then purified, and the polypeptide can be treated with proteolytic enzymes, for example, trypsin and carboxypeptidase B, to produce the finished insulin.
- Concentration of the refolded polypeptide can be carried out using any convenient technique, such as ultrafiltration or chromatography (e.g., ion exchange, hydrophobic or affinity chromatography) and the like.
- the concentration process if desired, may also include a buffer replacement process.
- the concentration is carried out at a reduced temperature (for example, about 4-10 degrees C).
- Proteolytic cleavage of the insulin precursor is carried out either by simultaneous treatment with trypsin and carboxypeptidase B or by separate treatment with these two enzymes. Trypsin is used in a concentration of from about 1: 200 to 1: 20,000 (enzyme hubbrate, weight ratio), while carboxypeptidase B is used in a concentration of from about 1: 100 to 1: 5000.
- Proteolytic cleavage is carried out in a buffer with a pH of approximately 7.5 to 11.0, preferably pH 10.5; the addition of Ca 2+ , Zn 2+ , Mn 2+ , Mg ions can improve the reaction efficiency.
- the incubation temperature ranges from 0 degrees C to about 30 degrees C, mainly about 6 degrees C, the incubation time from 1 to 24 hours, mostly about 14 hours.
- PCR polymerase chain reaction
- Primer Pl coincides with the sequence of the B-chain of the human insulin gene, starting with Arg 22 of human preproinsulin, and contains the recognition site of the Ndel endonuclease (highlighted by a frame) necessary for cloning.
- the reverse primer (P2) is complementary to the amino terminal fragment of the insulin A chain and contains an EcoRI region (outlined) for cloning purposes. PCR reaction was carried out in a solution that contained 25 pmol of each of these primers,
- PCR fragment about 280 bp long was isolated from an agarose gel and cloned into a pTA cloning vector.
- the ligase mixture was introduced into the Escherichia coli strain DH5alpha, transformants were selected on plates with LB agar medium containing ampicillin. Several individual colonies were grown in LB medium overnight, plasmid DNA was isolated with using the Wizard minipreps DNA kit isolatiop kit. Clone IK8 was selected for subsequent work because it had the correct DNA sequence.
- plasmid DNA isolated from clone IK8 was digested with restriction endonucleases Ndel and EcoRI; DNA fragment about 270 bp long was isolated from an agarose gel and cloned into the plasmid pET28a, which was digested with the same enzymes and treated with alkaline phosphatase from the calf’s stomach.
- the Escherichia coli DH5alpha strain was transformed with a ligase mixture and transformants were selected on LBA kanamycin plates. Plasmid DNA was isolated from some transformants and analyzed by restriction with Ndel and EcoRI. The correct clone has been identified and named pIK8-proins. This plasmid was subsequently introduced into Escherichia coli, for example, strain JMl 09 or BL21.
- Plasmid DNA pIK8-proins was used as a template for targeted mutagenesis using PCR and the following primers:
- PCR reaction conditions were as follows: 94 degrees C, 3 sec; 59 degrees C, ZOsek; 72 degrees C, 6 minutes and final synthesis at 72 degrees C in for 10 minutes.
- the product of the NDP reaction was purified by a Zumosleap kit and treated with 10 U restriction enzyme Dpl to remove the original matrix. After another purification cycle on a 2 ⁇ l column, an aliquot was introduced into Escherichia coli strain DH5alpha and transformants were selected on LB plates that contain kanamycin.
- plasmid DNA was isolated using a set of Wizard mipers. Clone MUTl 2 was selected for subsequent work because it had the correct DNA sequence. For expression in Escherichia coli, this plasmid was subsequently introduced into Escherichia coli, for example, strain JMl 09 or BL21.
- oligonucleotide seeds based on the published amino acid sequence of human insulin [10].
- codons of nutleotid seeds corresponded to the presence of Escherichi coli genes with a high level of expression [11] and the level of tRNA in Escherichi coli [12]. These seeds also contained sites of recognition of endonucleases in various positions - for the purpose of cloning.
- the mixture of primers Sl, S2, S3, S4 (final concentration of 2 ⁇ m each) in a PCR buffer solution containing 5U r ⁇ th polymerase DNA was heated to 94 degrees C for 1 minute, cooled to 62 degrees C and reacted at 72 degrees C for 2 minutes to fill the gaps.
- the following 20 cycles of amplification were performed under the following conditions: 94 degrees C, 15 sec; 62 degrees C, 30 sec; 72 degrees C, 30 sec. 2 ⁇ l of the above mixture was used as a template for amplification of human proinsulin cDNA using Sl and S5 primers.
- PCR fragment of approximately 180 bp in length was gel purified and cloned into a pTA-cloning vector. Clone IS2 was selected for subsequent work because it had the correct DNA sequence.
- plasmid DNA isolated from clone IS2 was digested with restriction endonucleases Ndel and EcoRI; DNA fragment with a length of about 170 bp was isolated from an agarose gel and cloned into the plasmid pET28a, which was digested with the same enzymes and treated with alkaline phosphatase from the calf’s stomach.
- the Escherichia coli DH5alpha strain was transformed with a ligase mixture and transformants were selected on LB kanamycin plates. Plasmid DNA was isolated from some transformants and analyzed by restriction with Ndel and EcoRI. The correct clones were identified and named pISYN2. This plasmid was subsequently introduced into Escherichia coli, for example, strain JM109 or BL21.
- the plasmid DNA pMUT12 was used as a template for amplification of human pro-insulin cDImi-mi with a modified prepeptide. PCR reaction was carried out under the conditions described in example 1 using the following primers:
- PCR product with a length of approximately 210 bp was isolated from agarose gel and cloned into a pTA vector.
- the ligase mixture was transformed into an Escherichia coli strain DHZalpha and transformants were selected on LB plates that contain ampicillin. Clone CEM6 was selected as such that has the correct DNA sequence.
- plasmid DNA isolated from clone CIM6 was treated with restriction endonucleases Ndel and HipdSh.
- a DNA fragment of approximately 200 bp in length was isolated from the gel and cloned into the plasmid pET39a treated with the same enzymes.
- the ligase mixture was transformed into Escherichia coli DH5alpha and transformants were selected on LB plates with kanamycin.
- Plasmid DNA was isolated from several transformants and analyzed by cleavage of Ndel and Hipd ⁇ II. The correct clone has been identified and named pGMBL. This plasmid was transformed into Escherichia coli, for example, strain JMl 09 or BL21.
- the plasmid DNA pMUT12 was used as a template for amplification of human proinsulin cDNAmshi with a modified prepeptide. PCR reaction was carried out under the conditions described in example 1 using the following primers: Primer D (direct):
- plasmid DNA isolated from the DIMl clone was treated with restriction endonucleases Ncl and SchipdP.
- a DNA fragment of approximately 200 bp in length was isolated from the gel and cloned into the plasmid pET28a treated with the same enzymes.
- the ligase mixture was transformed into Escherichia coli DH5alpha and transformants were selected on LB plates with kanamycin.
- Plasmid DNA was isolated from several transformants and analyzed by cleavage of Ncol and Hipd III. The correct clone has been identified and named pDIM07. This plasmid was transformed into Escherichia coli, for example, strain JMl 09 or BL21.
- the bacterial culture was centrifuged at 4000 rpm for 15 min in order to obtain a pellet of E. coli cells.
- Cells were lysed by heating to 95 degrees C for 5 min in the buffer for applying samples, lysates were analyzed by PAGE electrophoresis under denaturing conditions according to standard methods [13].
- a flask with sterile LB medium supplemented with 30 ⁇ g / ml kanamycin or 50 ⁇ g / ml ampicillin was seeded with a culture bank and incubated for 15 hours on a shaker at 37 degrees C and approximately 250 rpm. If necessary, the following stages of cultivation were carried out in aerated fermenters with stirring.
- the sterile medium in the fermenter was seeded with a bacterial culture from the flask (inoculum volume was 5-10% of the fermenter volume), incubation was carried out for 5-8 hours at 37 degrees C, pH 6.9 ⁇ 0.5 with stirring and aeration to maintain the level of dissolved oxygen above 20% saturation.
- the production medium was seeded with a sowing crop (1-10% of the volume of the working fermenter) and incubated at 37 degrees C. Stirring-aeration was set at a level sufficient to maintain the level of dissolved oxygen above 20% saturation. The pH was maintained at 6.9 ⁇ 0.5 with NH 4 OH. Propinol B400 was used as an antifoam.
- a sterile solution of 50% glucose was used as a carbon source. Once cell concentration reached OD ⁇ oo 30, inductor sterile solution, e.g. IPTG (final concentration 1 mM) was infused and the culturing was continued for 6 hours, cell concentration reached at approximately 50 OD b oo- The culture medium is then cooled and the cells harvested by centrifugation.
- inductor sterile solution e.g. IPTG (final concentration 1 mM) was infused and the culturing was continued for 6 hours, cell concentration reached at approximately 50 OD b oo- The culture medium is then cooled and the cells harvested by centrifugation.
- the bacterial mass was resuspended (in the ratio of the buffer solution 1:10) in a cold buffer solution, which contains 20 mm Tris, pH 7.5; IMM EDTA AND 100 mM NaCl.
- a cell suspension was passed through a cell disruptor at 17,000 psi and inclusion bodies were collected by centrifugation.
- the precipitate which contains inclusion bodies and bacterial fragments, was washed with a 20-fold volume of cold (+ 10 degrees C) buffer for washing, which contains 1.0% Tritop X100, 20 mm Tris-Hcl, pH 8.0; 2 mM EDTA, 100 mM NaCl.
- the precipitate was collected by centrifugation at approximately 14,000 rpm. The washing step was repeated twice.
- aqueous suspension of inclusion bodies with a volume of 60 l with a total protein content of 12 kg was treated with lysozyme (0.1 mg / ml), RNase (0.5 unit / ml) and DNase (0.5 unit / ml) for 3 hours at 25 ° C in a buffer that contains 20 mm Tris-Hcl, pH 7.5; 10 mM MgSO 4 . After treatment, the nucleic acid content was determined, which was 198 mr / l (656 mg / l - before treatment).
- Inclusion bodies were washed from excess enzymes by centrifugation and dissolved in 100 L of a buffer solution that contains 8M urea, 20 mM glycine, pH 8.5; IMM EDTA, 150 mM ⁇ -mercaptoethanol. Incubation continued for 4 hours at room temperature. The solution was clarified by high speed centrifugation and the reconstituted insulin precursor was used for refolding.
- Concentration of the refolded polypeptide is usually carried out by ultrafiltration or using absorption chromatography. Chromatographic column 450x500 mm. 30 l of polymer sorbent ⁇ mb Canalriquehr Albanym CG-300M was filled. The refolded reaction mixture was fed to the column at a flow rate of 4 L / min, and the column was washed with three volumes of equilibration buffer. The polypeptide was eluted with 20-40% 2-propanol solution. Then, the eluent was analyzed by high performance liquid chromatography, which showed the purity of the resulting preparation is more than 45%, and the yield is at least 96%.
- the refolding tank was filled with buffer (10 mM glycine, IMM EDTA, 2 mM cystine, lg / l PEG1500, pH 11.2) and cooled to 1O 0 C. 50 l of the recovered hybrid protein was mixed with 5000 l of refolding buffer, the protein concentration in the tank for refolding is 0.5 g / l.
- the insulin precursor in a solution of 50 mM Tris-Hcl, pH 8.0 was digested to human insulin by incubation with trypsin (1: 8000; weight ratio) and carboxypeptidase B (1: 2000; weight ratio) in the presence of l, 5mM Zn 2+ .
- the reaction was carried out for 16 hours. at 8 degrees C and stopped by adjusting the pH to 2.5 with 6M HCl. High performance liquid chromatographic analysis showed that the purity of the resulting preparation was 69% or more. Insulin can be precipitated from the reaction mixture with ammonium sulfate or sodium chloride (final concentration of 20%).
- insulin crystals were dissolved at pH 3.0 in a solution that contained 0.05 M sodium acetate and 10% 2-propanol and was filtered through a 0.2 ⁇ m filter.
- the resulting solution at a rate of 0.8 l / min was applied to a 200x600 mm column filled with 19 l of sorbent, for example Diasogel SP-120-20-ODS-AP.
- the column was pre-equilibrated with 40 L of application buffer (0.05 M sodium acetate, 10% 2-propanol, pH 3.0); the column was washed with the same buffer solution after insulin application. Elution of insulin was carried out by a linear gradient of 2-propanol (10-28%).
- the column was washed with 50 L of a solution that contains 0.05 M potassium acetate, 50% 2-propanol, pH 3.0. Analysis showed that the purity of insulin was at least 98%.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801545154A CN102282260A (zh) | 2008-11-26 | 2009-06-16 | 用于制备人重组胰岛素的方法 |
EA201100781A EA201100781A1 (ru) | 2008-11-26 | 2009-06-16 | Способ получения рекомбинантного инсулина человека |
EP09829420A EP2374888A4 (en) | 2008-11-26 | 2009-06-16 | PROCESS FOR PRODUCING RECOMBINANT HUMAN INSULIN |
BRPI0920482-2A BRPI0920482A2 (pt) | 2008-11-26 | 2009-06-16 | método para produção de insulina recombinante humana |
CA2746984A CA2746984A1 (en) | 2008-11-26 | 2009-06-16 | Method for preparing of human recombinant insulin |
US13/116,822 US20120058513A1 (en) | 2008-11-26 | 2011-05-26 | Method for producing human recombinant insulin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200813678 | 2008-11-26 | ||
UAA200813678A UA91281C2 (ru) | 2008-11-26 | 2008-11-26 | Способ получения рекомбинантного инсулина человека |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/116,822 Continuation US20120058513A1 (en) | 2008-11-26 | 2011-05-26 | Method for producing human recombinant insulin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010062279A1 true WO2010062279A1 (ru) | 2010-06-03 |
Family
ID=42225939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/UA2009/000025 WO2010062279A1 (ru) | 2008-11-26 | 2009-06-16 | Способ получения рекомбинантного инсулина человека |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120058513A1 (ru) |
EP (1) | EP2374888A4 (ru) |
CN (1) | CN102282260A (ru) |
BR (1) | BRPI0920482A2 (ru) |
CA (1) | CA2746984A1 (ru) |
EA (1) | EA201100781A1 (ru) |
UA (1) | UA91281C2 (ru) |
WO (1) | WO2010062279A1 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2447149C1 (ru) * | 2011-03-24 | 2012-04-10 | Винсорт Менеджемент Инк | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pMSIN4, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД - ПРЕДШЕСТВЕННИК ИНСУЛИНА ЧЕЛОВЕКА, ШТАММ BL21(DE3)/pMSIN4-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА |
WO2012152439A1 (en) * | 2011-05-10 | 2012-11-15 | Glucometrix Ag | Comprehensive buffer system for renaturing human proinsulin or proinsulin derivatives |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014099577A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | Process for purifying insulin and analogues thereof |
BR112015031277A2 (pt) | 2013-06-14 | 2017-09-19 | Harvard College | Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos |
WO2015066345A1 (en) * | 2013-10-30 | 2015-05-07 | NorthStar Medical Radioisotopes LLC | Separator cartridge for radionuclide |
CN103694339B (zh) * | 2013-12-04 | 2017-10-13 | 珠海联邦制药股份有限公司 | 一种甘精胰岛素前体的复性方法 |
WO2016144658A1 (en) * | 2015-03-10 | 2016-09-15 | Merck Sharp & Dohme Corp. | Process for preparing recombinant insulin using microfiltration |
US20180291077A1 (en) * | 2015-09-24 | 2018-10-11 | Hanmi Pharm. Co., Ltd | Method of insulin production |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76661C2 (en) | 2005-04-06 | 2006-08-15 | Omakooe Ltd Liability Company | A method for producing recombinant humanæs insulin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4405179A1 (de) * | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
KR100253916B1 (ko) * | 1997-12-29 | 2000-05-01 | 김충환 | 사람 인슐린 전구체의 제조방법 |
US20060035316A1 (en) * | 2002-11-12 | 2006-02-16 | Sang-Yong Lee | Plasmids expressing human insulin and the preparation method for human insuling thereby |
-
2008
- 2008-11-26 UA UAA200813678A patent/UA91281C2/ru unknown
-
2009
- 2009-06-16 CN CN2009801545154A patent/CN102282260A/zh active Pending
- 2009-06-16 EP EP09829420A patent/EP2374888A4/en not_active Withdrawn
- 2009-06-16 CA CA2746984A patent/CA2746984A1/en not_active Abandoned
- 2009-06-16 EA EA201100781A patent/EA201100781A1/ru unknown
- 2009-06-16 BR BRPI0920482-2A patent/BRPI0920482A2/pt not_active IP Right Cessation
- 2009-06-16 WO PCT/UA2009/000025 patent/WO2010062279A1/ru active Application Filing
-
2011
- 2011-05-26 US US13/116,822 patent/US20120058513A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76661C2 (en) | 2005-04-06 | 2006-08-15 | Omakooe Ltd Liability Company | A method for producing recombinant humanæs insulin |
Non-Patent Citations (15)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2447149C1 (ru) * | 2011-03-24 | 2012-04-10 | Винсорт Менеджемент Инк | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pMSIN4, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД - ПРЕДШЕСТВЕННИК ИНСУЛИНА ЧЕЛОВЕКА, ШТАММ BL21(DE3)/pMSIN4-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА |
WO2012152439A1 (en) * | 2011-05-10 | 2012-11-15 | Glucometrix Ag | Comprehensive buffer system for renaturing human proinsulin or proinsulin derivatives |
Also Published As
Publication number | Publication date |
---|---|
BRPI0920482A2 (pt) | 2019-09-24 |
CA2746984A1 (en) | 2010-06-03 |
UA91281C2 (ru) | 2010-07-12 |
EP2374888A4 (en) | 2012-06-06 |
CN102282260A (zh) | 2011-12-14 |
US20120058513A1 (en) | 2012-03-08 |
EP2374888A1 (en) | 2011-10-12 |
EA201100781A1 (ru) | 2012-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010062279A1 (ru) | Способ получения рекомбинантного инсулина человека | |
CA2605140C (en) | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein | |
CN111072783B (zh) | 一种采用大肠杆菌表达串联序列制备glp-1或其类似物多肽的方法 | |
US8298789B2 (en) | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) | |
JP2008521415A (ja) | カルボキシ末端をアミド化したペプチドの製造方法 | |
AU607973B2 (en) | Process for production of physiologically active peptide containing cysteine residue | |
CN113105536B (zh) | 一种新甘精胰岛素原及其制备甘精胰岛素的方法 | |
WO2020051812A1 (zh) | 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法 | |
US10000544B2 (en) | Process for production of insulin and insulin analogues | |
WO2007112677A1 (fr) | Procédé de préparation d'hormone parathyroïdienne humaine 1-34 | |
JP2637393B2 (ja) | プロインシュリンおよびプレプロインシュリン産生暗号を有するヒト遺伝子 | |
CN111303275A (zh) | 一种重组人生长激素及其制备方法与药物应用 | |
EP1001980A1 (en) | Recombinant expression of insulin c-peptide | |
WO1997001627A1 (en) | High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli | |
Liu et al. | Large scale preparation of recombinant human parathyroid hormone 1–84 from Escherichia coli | |
CN106749615A (zh) | 一种大菱鲆生长催乳素sl基因、重组蛋白及其制备方法 | |
CN113249288B9 (zh) | 一种表达glp-1类似物的重组菌及其应用 | |
RU2447149C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pMSIN4, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД - ПРЕДШЕСТВЕННИК ИНСУЛИНА ЧЕЛОВЕКА, ШТАММ BL21(DE3)/pMSIN4-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНСУЛИНА ЧЕЛОВЕКА | |
CN114933658A (zh) | 一种短肽元件及其应用方法 | |
WO2009054754A1 (fr) | Plasmide recombinant phins21 codant une protéine hybride avec la proinsuline humaine, souche de bactéries escherichia coli jm109/ phins21 productrice de la protéine hybride avec la proinsuline humaine et procédé de fabrication de proinsuline humaine | |
JP4886654B2 (ja) | ヒト成長ホルモンの効率化された製造方法 | |
WO2020053875A1 (en) | Process for producing recombinant peptides | |
CN116217699A (zh) | 一种高效表达羊生长激素的方法 | |
WO2016034534A1 (en) | Lysine rich basic pre-sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980154515.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09829420 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009829420 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2746984 Country of ref document: CA Ref document number: 201100781 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2617/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001387-2011 Country of ref document: PE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0920482 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01D Ref document number: PI0920482 Country of ref document: BR Free format text: O PRESENTE PEDIDO FOI DEPOSITADO ATRAVES DO PCT/UA2009/000025 EM 16/06/2009, DANDO ENTRADA NA FASE NACIONAL EM 26/07/2011, APESAR DO PRAZO EXPIRAR EM 26/05/2011 (30 MESES CONTADOS DA DATA DE PRIORIDADE QUE E 26/11/2008). O DEPOSITANTE SOLICITOU CONCESSAO DE PRAZO ADICIONAL OU RESTABE NA FORMA DA RESOLUCAO 254 DE 13 DE JULHO DE 2010, JUSTIFICANDO QUE POR MOTIVO TOTALMENTE IMPREVISTO, ALHEIO A VONTADE DA PARTE, NAO FOI POSSIVEL REALIZAR O DEPOSITO DENTRO DO PRAZO. O REQUERENTE ALEGA QUE, "DEVIDO A PESSIMAS CONDICOES CLIMATICAS E DE UM FURACAO QUE CAUSOU A PERDA DE ENERGIA ELETRICA EM DIVERSAS REGIOES DA UCRANIA, NAO FOI POSSIVEL DEPOSITAR O PEDIDO NO PRAZO LEGAL". COM BASE NO CODIGO CIVIL E NO |
|
ENP | Entry into the national phase |
Ref document number: PI0920482 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110726 |